Novel Drug Better Than Wegovy? New Endocrine Society Prez; Knockoff Tirzepatide Woes

In a phase I trial, investigational amycretin led to greater weight loss compared with historical benchmarks set by semaglutide (Wegovy), according to drugmaker Novo Nordisk. (Forbes)

Use of the Omnipod 5 automated insulin delivery system for type 1 diabetes led to 17.5% greater time spent in range (70 to 180 mg/dL) compared with insulin pump therapy in a trial, said maker Insulet.

The Endocrine Society elected Carol Lange, PhD, of the University of Minnesota in Minneapolis, as its 2025-2026 president.

The Congressional Budget Office suggested that obesity drugs like semaglutide may soon be covered by Medicare, in part due to recent findings about heart benefits. (Endpoint News)

Bacteria and high levels of impurities were found in products claiming to be compounded versions of tirzepatide (Mounjaro, Zepbound). (Reuters)

Meanwhile, tirzepatide-maker Eli Lilly’s new ad campaign urges against using weight-loss drugs for “vanity” reasons. (CNN)

Younger women exposed to neighborhood poverty in adulthood were more likely to have a lower ovarian reserve. (Menopause)

Girls are hitting puberty earlier and earlier in recent years. (STAT)

New research is casting doubts about whether or not cutting calories helps with symptoms of polycystic ovary syndrome. (New York Times)

Calcium and vitamin D supplements appeared to reduce cancer mortality and raise cardiovascular disease mortality in post-menopausal women after more than 20 years of follow-up. (Annals of Internal Medicine)

One center boosted kidney transplant rates for patents with obesity and end-stage renal disease by first having them undergo bariatric surgery. (Journal of the American College of Surgeons)

Elevated metabolic syndrome scores for long periods of time were associated with an increased risk of various cancers, a prospective cohort study found. (Cancer)

Please enable JavaScript to view the

comments powered by Disqus.